Cullinan Therapeutics, Inc. (NASDAQ:CGEM - Get Free Report) shares fell 4.7% during trading on Thursday . The stock traded as low as $8.48 and last traded at $8.64. 52,264 shares changed hands during trading, a decline of 91% from the average session volume of 570,932 shares. The stock had previously closed at $9.07.
Analysts Set New Price Targets
Several brokerages have commented on CGEM. UBS Group cut their target price on Cullinan Therapeutics from $30.00 to $24.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Morgan Stanley reaffirmed an "overweight" rating and set a $35.00 target price (down from $38.00) on shares of Cullinan Therapeutics in a report on Friday, March 7th. Finally, HC Wainwright reissued a "buy" rating and issued a $33.00 price objective on shares of Cullinan Therapeutics in a research note on Wednesday, April 16th.
Get Our Latest Research Report on CGEM
Cullinan Therapeutics Stock Performance
The company has a market capitalization of $535.86 million, a price-to-earnings ratio of -3.20 and a beta of -0.04. The business has a 50 day moving average price of $7.96 and a 200-day moving average price of $9.62.
Cullinan Therapeutics (NASDAQ:CGEM - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.74) earnings per share for the quarter, topping analysts' consensus estimates of ($0.78) by $0.04. As a group, equities analysts predict that Cullinan Therapeutics, Inc. will post -3.04 EPS for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the company. Brooklyn Investment Group bought a new stake in Cullinan Therapeutics in the 1st quarter worth about $34,000. Federated Hermes Inc. boosted its stake in shares of Cullinan Therapeutics by 67.0% in the 4th quarter. Federated Hermes Inc. now owns 3,802 shares of the company's stock worth $46,000 after buying an additional 1,525 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Cullinan Therapeutics by 1,214.8% in the first quarter. GAMMA Investing LLC now owns 6,995 shares of the company's stock valued at $53,000 after acquiring an additional 6,463 shares in the last quarter. Virtus ETF Advisers LLC grew its holdings in shares of Cullinan Therapeutics by 37.8% in the fourth quarter. Virtus ETF Advisers LLC now owns 5,828 shares of the company's stock valued at $71,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Aquatic Capital Management LLC purchased a new stake in shares of Cullinan Therapeutics during the fourth quarter valued at approximately $77,000. 86.31% of the stock is owned by institutional investors.
Cullinan Therapeutics Company Profile
(
Get Free Report)
Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.
Read More
Before you consider Cullinan Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cullinan Therapeutics wasn't on the list.
While Cullinan Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.